Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts broadly favor Arrowhead Pharmaceuticals: Nine of 13 analysts rate the stock a buy, three recommend holding and one recommends selling, resulting in a “Moderate Buy” consensus and an average 12-month price target of $98.42.
• ARWR opened at $85.37, near its 12-month high of $95.49, with a market capitalization of about $12.02 billion. Its latest quarter showed revenue growth of 171% year over year to $75.25 million, but the company reported an adjusted loss of $1.36 per share, missing estimates.
• Institutional ownership is substantial: Hedge funds and other institutional investors hold 62.61% of shares, while two directors recently sold stock and company insiders collectively own 3.60% of the company.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $98.4167.

Several analysts have recently issued reports on ARWR shares. B. Riley Financial upped their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Wall Street Zen upgraded Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, June 27th. Morgan Stanley upped their target price on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday. Finally, Piper Sandler reiterated an "overweight" rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $85.37 on Thursday. The company has a fifty day simple moving average of $83.82 and a 200 day simple moving average of $74.07. Arrowhead Pharmaceuticals has a 12-month low of $25.61 and a 12-month high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The company has a market cap of $12.02 billion, a P/E ratio of -37.94 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm's quarterly revenue was up 171.0% on a year-over-year basis. During the same period last year, the business posted ($1.26) earnings per share. Sell-side analysts predict that Arrowhead Pharmaceuticals will post -3.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael S. Perry sold 11,600 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director owned 111,459 shares of the company's stock, valued at $9,730,370.70. This trade represents a 9.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently modified their holdings of ARWR. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Arrowhead Pharmaceuticals in the second quarter valued at approximately $3,533,000. California State Teachers Retirement System raised its stake in shares of Arrowhead Pharmaceuticals by 7,797.6% in the second quarter. California State Teachers Retirement System now owns 11,397,217 shares of the biotechnology company's stock valued at $928,987,000 after buying an additional 11,252,904 shares during the period. Washington Trust Advisors Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 3.6% during the 2nd quarter. Washington Trust Advisors Inc. now owns 26,185 shares of the biotechnology company's stock valued at $2,134,000 after buying an additional 911 shares during the last quarter. Compass Financial Management LLC bought a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth $179,000. Finally, AlphaGrep UK Ltd purchased a new stake in Arrowhead Pharmaceuticals in the 2nd quarter worth about $375,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source